These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 32279936)

  • 41. Neoadjuvant chemotherapy followed by surgery in lung cancer: Indian scenario.
    Kumar S; Saikia J; Kumar V; Malik PS; Madan K; Jain D; Bharati S
    Curr Probl Cancer; 2020 Jun; 44(3):100563. PubMed ID: 32265058
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).
    Cottrell TR; Thompson ED; Forde PM; Stein JE; Duffield AS; Anagnostou V; Rekhtman N; Anders RA; Cuda JD; Illei PB; Gabrielson E; Askin FB; Niknafs N; Smith KN; Velez MJ; Sauter JL; Isbell JM; Jones DR; Battafarano RJ; Yang SC; Danilova L; Wolchok JD; Topalian SL; Velculescu VE; Pardoll DM; Brahmer JR; Hellmann MD; Chaft JE; Cimino-Mathews A; Taube JM
    Ann Oncol; 2018 Aug; 29(8):1853-1860. PubMed ID: 29982279
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
    Couñago F; Montemuiño S; Martin M; Taboada B; Calvo-Crespo P; Samper-Ots MP; Alcántara P; Corona J; López-Guerra JL; Murcia-Mejía M; López-Mata M; Jové-Teixidó J; Chust M; Díaz-Díaz V; de Ingunza-Barón L; García-Cañibano T; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Puertas MM; Thuissard IJ; Sanz-Rosa D; de Dios NR
    Clin Transl Oncol; 2019 Jun; 21(6):735-744. PubMed ID: 30430394
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neoadjuvant chemotherapy in stage III NSCLC.
    Allen J; Jahanzeb M
    J Natl Compr Canc Netw; 2008 Mar; 6(3):285-93. PubMed ID: 18377847
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with 
Chemotherapy in Resectable Non-small Cell Lung Cancer].
    Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
    Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Major Pathologic Response after Induction Therapy Has a Long-Term Impact on Survival and Tumor Recurrence in Stage IIIA/B Locally Advanced NSCLC.
    Schreiner W; Dudek W; Rieker RJ; Lettmaier S; Fietkau R; Sirbu H
    Thorac Cardiovasc Surg; 2020 Oct; 68(7):639-645. PubMed ID: 30808023
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study.
    Xu F; Zhu H; Xiong D; Wang K; Dong Y; Li L; Yuan S
    Thorac Cancer; 2024 Jan; 15(2):172-181. PubMed ID: 38057283
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Major pathological response exhibited distinct prognostic significance for lung adenocarcinoma post different modalities of neoadjuvant therapy.
    Xia L; Guo J; E H; Zhang W; Huang Y; Zhang L; Zhao D; Xie D; Wu C; Hou L
    Histopathology; 2023 Apr; 82(5):691-703. PubMed ID: 36579364
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).
    Kocher F; Pircher A; Mohn-Staudner A; Romeder F; Duller W; Steinmaurer M; Eckmayr J; Schmid T; Hilbe W; Fiegl M; Greil R
    Lung Cancer; 2014 Sep; 85(3):395-400. PubMed ID: 25043642
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of mediastinal lymph node status and relapse pattern in clinical stage IIIA non-small cell lung cancer patients treated with neoadjuvant chemotherapy versus upfront surgery: A single center experience.
    Savic M; Kontic M; Ercegovac M; Stojsic J; Bascarevic S; Moskovljevic D; Kostic M; Vesovic R; Popevic S; Laban M; Markovic J; Jovanovic D
    Thorac Cancer; 2017 Sep; 8(5):393-401. PubMed ID: 28671758
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: A phase II study.
    Zhang Y; Fu F; Hu H; Wang S; Li Y; Hu H; Chen H
    J Thorac Cardiovasc Surg; 2021 Feb; 161(2):434-442.e2. PubMed ID: 32340810
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
    Castello A; Toschi L; Rossi S; Finocchiaro G; Grizzi F; Mazziotti E; Qehajaj D; Rahal D; Lopci E
    Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
    Xu YP; Li B; Xu XL; Mao WM
    Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of different criteria for estimating major pathological response in resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
    Sun W; Liu X; Wang C; Jiang Y; Lin D
    Ann Diagn Pathol; 2024 Apr; 69():152268. PubMed ID: 38301396
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.
    Zhao K; Wang C; Shi F; Huang Y; Ma L; Li M; Song Y
    BMC Cancer; 2021 Jan; 21(1):66. PubMed ID: 33446134
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of neoadjuvant chemo-immunotherapy in non-small cell lung cancer: a real-world, multicenter, retrospective study.
    Wang X; Wang X; Hui B; Cai J; Zhao H; Qiao B; Duan J; Chen K; Wang J; Lei J; Yang F
    Transl Lung Cancer Res; 2024 Apr; 13(4):849-860. PubMed ID: 38736498
    [TBL] [Abstract][Full Text] [Related]  

  • 58. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
    Dacic S; Travis W; Redman M; Saqi A; Cooper WA; Borczuk A; Chung JH; Glass C; Lopez JM; Roden AC; Sholl L; Weissferdt A; Posadas J; Walker A; Zhu H; Wijeratne MT; Connolly C; Wynes M; Bota-Rabassedas N; Sanchez-Espiridion B; Lee JJ; Berezowska S; Chou TY; Kerr K; Nicholson A; Poleri C; Schalper KA; Tsao MS; Carbone DP; Ready N; Cascone T; Heymach J; Sepesi B; Shu C; Rizvi N; Sonett J; Altorki N; Provencio M; Bunn PA; Kris MG; Belani CP; Kelly K; Wistuba I;
    J Thorac Oncol; 2023 Oct; 18(10):1290-1302. PubMed ID: 37702631
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials.
    Song WA; Zhou NK; Wang W; Chu XY; Liang CY; Tian XD; Guo JT; Liu X; Liu Y; Dai WM
    J Thorac Oncol; 2010 Apr; 5(4):510-6. PubMed ID: 20107424
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response.
    Zens P; Bello C; Scherz A; Koenigsdorf J; Pöllinger A; Schmid RA; Ochsenbein A; Neppl C; Langer R; Berezowska S
    Mod Pathol; 2021 Jul; 34(7):1333-1344. PubMed ID: 33714982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.